| Literature DB >> 19616266 |
Ako Fukami1, Hisashi Adachi, Sho-ichi Yamagishi, Takanori Matsui, Shin-ichiro Ueda, Kazuo Nakamura, Mika Enomoto, Maki Otsuka, Shun-ichi Kumagae, Yasuki Nanjo, Eita Kumagai, Eishi Esaki, Kyoko Murayama, Yuji Hirai, Tsutomu Imaizumi.
Abstract
High mobility group box 1 (HMGB1), a nonhistone chromatin-associated protein, is implicated as a mediator of both infectious and non-infectious inflammatory conditions. Clinical research on this protein in humans just has begun; serum HMGB1 was reported to be elevated in a small number of critically ill patients suffering from sepsis. However, the kinetics, distribution and factors associated with circulating HMGB1 are unknown in a general population. In this study, we examined these issues in a large population of healthy subjects. Fasting blood samples were obtained from 626 subjects (237 males and 389 females). HMGB1 levels showed a skewed distribution with a mean of 1.65 +/- 0.04 ng/ml. Multiple stepwise regression analyses found that white blood cell (WBC) counts (P = .016) and the soluble form of receptor for advanced glycation end products (sRAGE; P < .001, inversely), which is also known to be a receptor for HMGB1, were independently associated with HMGB1 levels. We demonstrated for the first time that circulating HMGB1 levels were inversely associated with sRAGE levels in a general population. Because RAGE is involved in HMGB1 signaling, our present study suggests that sRAGE may capture and eliminate circulating HMGB1 in humans.Entities:
Mesh:
Substances:
Year: 2009 PMID: 19616266 DOI: 10.1016/j.metabol.2009.05.024
Source DB: PubMed Journal: Metabolism ISSN: 0026-0495 Impact factor: 8.694